Real-world evidence shows abrocitinib improves pruritus in atopic dermatitis patients, suggesting it has a favorable safety profile.
This real-world study supports clinical trial findings on the high effectiveness of abrocitinib in the management of AD. Moreover, it confirms that abrocitinib is generally well tolerated and can lead to early and sustained improvement in pruritus and overall QoL. Despite the small sample size, the results of the present real-world study seem to align with previous data on the effectiveness of abrocitinib also in the long-term management of AD, with an acceptable safety profile.
No takes yet. Share an insight, caveat, or question.
Tsiogka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: